Department of Anesthesiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.
Section of Emergency Medicine and Medical Toxicology, Department of Pediatrics, University of Colorado, Anschutz Medical Campus, Children's Hospital Colorado, Aurora, CO 80045, USA.
J Anal Toxicol. 2022 Apr 21;46(4):383-392. doi: 10.1093/jat/bkab030.
In recent years, the surge in use of tetrahydrocannabinol (THC) and cannabidiol (CBD) has increased the need for sensitive and specific analytical assays to measure the said compounds in patients, to establish dose-effect relationships and to gain knowledge of their pharmacokinetics and metabolism. We developed and validated an online extraction high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) method for simultaneous quantification of 17 cannabinoids and metabolites including THC and its metabolites, CBD and its metabolites and other minor cannabinoids in human plasma. CBD-glucuronide (CBD-gluc) standard was produced in-house by isolation of CBD-gluc from urine of patients using pure CBD oil. For calibration standards and quality control samples, human plasma was spiked with cannabinoids at varying concentrations within the working range of the respective compound and 200 µL of the plasma was extracted using a simple one-step protein precipitation procedure. The extracts were analyzed using online trapping LC/LC-atmospheric pressure chemical ionization-MS-MS running in the positive multiple reaction monitoring mode. The lower limit of quantification ranged from 0.78 to 7.8 ng/mL, and the upper limits of quantification were between 100 and 2,000 ng/mL. Inter-day analytical accuracy and imprecision ranged from 90.4% to 111% and from 3.1% to 17.4%, respectively. The analysis of plasma samples collected during clinical studies showed that (3R-trans)-cannabidiol-7-oic acid (7-CBD-COOH) was the major human metabolite with 5960% (59.6-fold) of CBD followed by 7-hydroxy-CBD (177%), CBD-gluc (157%) and 6α-hydroxy-CBD (39.8%); 6β-hydroxy-CBD was not detected in any of the samples. In the present study, we developed and validated a robust LC-MS-MS assay for the simultaneous quantification of cannabinoids and their metabolites, which has been used to measure >5,000 samples in clinical studies. Moreover, we were able to quantify CBD-gluc and showed that 7-CBD-COOH, 7-hydroxy-CBD and CBD-gluc are the major CBD metabolites in human plasma.
近年来,四氢大麻酚 (THC) 和大麻二酚 (CBD) 的使用激增,这增加了对灵敏和特异的分析检测方法的需求,以便在患者中测量这些化合物,建立剂量-效应关系,并了解其药代动力学和代谢情况。我们开发并验证了一种在线提取高效液相色谱-串联质谱 (HPLC-MS-MS) 方法,用于同时定量检测人血浆中的 17 种大麻素及其代谢物,包括 THC 及其代谢物、CBD 及其代谢物和其他少量大麻素。CBD-葡糖苷酸 (CBD-gluc) 标准品是通过使用纯 CBD 油从患者尿液中分离 CBD-gluc 而在内部产生的。对于校准标准品和质控样品,将不同浓度的大麻素加入到人血浆中,使其处于各自化合物的工作范围内,然后使用简单的一步蛋白沉淀程序提取 200μL 血浆。使用在线捕集 LC/大气压化学电离-MS-MS 在正多重反应监测模式下分析提取物。定量下限范围为 0.78 至 7.8ng/mL,定量上限范围为 100 至 2,000ng/mL。日间分析准确性和精密度范围分别为 90.4%至 111%和 3.1%至 17.4%。在临床研究中收集的血浆样品分析表明,(3R-trans)-大麻二酚-7-羧酸 (7-CBD-COOH) 是主要的人体代谢物,其 CBD 含量为 5960%(59.6 倍),其次是 7-羟基-CBD(177%)、CBD-葡糖苷酸(157%)和 6α-羟基-CBD(39.8%);在任何样本中均未检测到 6β-羟基-CBD。在本研究中,我们开发并验证了一种强大的 LC-MS-MS 分析方法,用于同时定量检测大麻素及其代谢物,该方法已用于测量 >5000 个临床研究样本。此外,我们能够定量检测 CBD-葡糖苷酸,并表明 7-CBD-COOH、7-羟基-CBD 和 CBD-葡糖苷酸是人体血浆中 CBD 的主要代谢物。